Clinical trials
Diagnose Disease clinical trials
Below are recruiting diagnose disease clinical trials, each written for real people, not researchers. We’re tracking 79 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05914662RecruitingPhase 2
Zanubrutinib plus BR for newly diagnosed symptomatic WM
This Phase 2 trial studies zanubrutinib combined with BR (bendamustine and rituximab) in adults newly diagnosed with Waldenström macroglobulinemia (WM) who have symptoms. It may help shrink the abnormal disease and improve symptoms like high blood stickiness, nerve problems, anemia, and other lymphoma-related issues.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06158269RecruitingPhase 2
DVRd treatment for newly diagnosed double-hit myeloma
This trial tests a combination of four drugs (daratumumab, bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with a high-risk form of multiple myeloma called double-hit myeloma. It aims to see if this drug combo can improve outcomes for those with two or more high-risk genetic changes.
TianjinAges 18–70 - NCT05573802RecruitingPhase 1/Phase 2
Belantamab and other medicines for new multiple myeloma
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
AthensAges 18 years+ - NCT06495021Recruiting
Osteopathic manipulation for newly diagnosed respiratory illness in older adults
This study tests whether osteopathic manipulation (a gentle hands-on treatment) helps older adults recover from common respiratory illnesses like bronchitis or pneumonia when added to regular care. It may be a good option for you if you're 65 or older and have just been diagnosed with a respiratory infection.
Bloomsburg, PennsylvaniaAges 65–100 - NCT07409454RecruitingPhase 2
Post-transplant treatment for multiple myeloma with a bispecific antibody
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
TianjinAges 18 years+ - NCT06212479Recruiting
Whole-body MRI for Preventive Health Screening
This study uses whole-body MRI to see if it can find health issues early in people without symptoms. The goal is to learn if this scan can help predict clinically important conditions in routine preventive care.
Watertown, MassachusettsAges 18 years+ - NCT06386302Recruiting
Chidamide, venetoclax, and azacitidine for new AML
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06611839RecruitingPhase 1/Phase 2
Combination therapy for IDH1-mutated AML
This trial tests a combination of three drugs (venetoclax, ivosidenib, and azacitidine) for people newly diagnosed with a specific type of AML that has an IDH1 mutation. The goal is to see if this mix works better than standard treatments.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT07151690RecruitingPhase 2
BCMA/CD3 bispecific antibody for newly diagnosed AL amyloidosis
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
TianjinAges 18 years+ - NCT05886049RecruitingPhase 1
Testing a menin drug with standard chemo for newly diagnosed AML
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
Orange, CaliforniaAges 18–75 - NCT07044687RecruitingPhase 4
Venetoclax with azacitidine for newly diagnosed AML
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
Gurgaon, HaryanaAges 18 years+ - NCT07106710RecruitingPhase 2
Stem cell transplant plus two targeted therapies for ultra-high-risk myeloma
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT00001276Recruiting
Understanding and Treating Severe Low Blood Sugar
This study helps doctors diagnose and treat dangerously low blood sugar, especially in people with pancreatic tumors that produce too much insulin. You'll receive comprehensive evaluation and personalized care to manage your condition.
Bethesda, MarylandAges 18–120 - NCT07490288Recruiting
Venetoclax, azacitidine, and mitoxantrone for new AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
Tianjin, Tianjin MunicipalityAges 14–100 - NCT05091372RecruitingPhase 2
Maintenance treatment after transplant for newly diagnosed myeloma
This trial tests whether using belantamab mafodotin plus lenalidomide as long-term maintenance after an autologous stem cell transplant can keep multiple myeloma under control, guided by minimal residual disease (MRD). MRD is a very small amount of disease that may remain after transplant, and the study helps see if treating those patients better improves outcomes.
Houston, TexasAges 18 years+ - NCT06023641RecruitingPhase 2
Liposomal irinotecan for children with rhabdomyosarcoma
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
Palo Alto, CaliforniaAges Up to 22 years - NCT06561880RecruitingPhase 1/Phase 2
Three-drug combo for FLT3-mutated AML
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT06449885Recruiting
Observational study for newly diagnosed MZL
This study is for people who were just diagnosed with marginal zone lymphoma (a slow-growing blood cancer) and haven't started treatment yet. Researchers will collect blood and tissue samples and follow you over time to learn more about the disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06658834RecruitingPhase 2
Romiplostim for newly diagnosed ITP in adults
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07493161Recruiting
Chemo with targeted therapy for new Ph+ ALL
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT07585760RecruitingPhase 2
Study of CM336 and Isatuximab for new multiple myeloma with kidney problems
This trial tests a combination of two drugs, CM336 and Isatuximab, for people newly diagnosed with multiple myeloma that has caused kidney damage. The goal is to see if this treatment can help control the myeloma while also addressing the kidney issues.
TianjinAges 18–80 - NCT06481241Recruiting
Chemotherapy plus CAR-T for newly diagnosed Ph- B-ALL
This trial tests giving chemotherapy together with a special immune cell treatment called CAR-T cells for adults who have just been diagnosed with a specific type of leukemia (Ph- B-ALL). The goal is to see if this combination works better than standard treatment.
TianjinAges 18 years+ - NCT06992128RecruitingPhase 2
Romiplostim plus steroids for newly diagnosed ITP
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07095452RecruitingPhase 2/Phase 3
Newly diagnosed myeloma: comparing drug combinations for non-transplant patients
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
Scottsdale, ArizonaAges 18 years+
Hear when a new Diagnose Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diagnose disease?
- Yes. Clin2 currently lists 79 recruiting diagnose disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diagnose disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diagnose disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.